<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Materials Science and Engineering</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0375F088-818A-437C-9B0F-0610197366AB"><gtr:id>0375F088-818A-437C-9B0F-0610197366AB</gtr:id><gtr:firstName>Sheila</gtr:firstName><gtr:surname>MacNeil</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401428"><gtr:id>62047644-97E5-4E00-8AE7-79CF16E135F0</gtr:id><gtr:title>Anti-Inflammatory Hydrogels for Topical Use following Excision of Primary Melanoma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401428</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>58578</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention relates to a wound dressing comprising an electrospun scaffold. The scaffold comprises a biodegradable polymer or co-polymer and a nonsteroidal anti-inflammatory drug (NSAID). The biodegradable polymer or co-polymer is preferably biocompatible. One such co-polymer is a polyp(D,L-lactic-co-glycolide. The NSAID may be a propionic NSAID such as [2-(4-isobutylphenyl)propionic acid] (ibuprofen) or it may be acetylsalicylic acid (aspirin). Preferably, the scaffold comprises between 5-30% by weight of NSAID. The polymer or co-polymer may be capable of each dissolving in a common solvent. Also disclosed is a method of forming an electrospun scaffold and a method of treating a wound using the dressing.</gtr:description><gtr:grantRef>G0401428</gtr:grantRef><gtr:id>F8631D6A-B516-436B-8361-38C48B85A8DC</gtr:id><gtr:impact>The commercial aspects of this work have been recognised and patent applications have been filed in the UK and the USA. The University of Sheffield's technology transfer company Biofusion is currently attempting to secure licensing agreements with external corporations on aspects of this technology.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>B15tX4ZmHpY</gtr:outcomeId><gtr:patentId>GB2468503</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>A dressing comprising an electrospun scaffold and a nonsteroidal anti-inflammatory drug</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1378503A-6C29-43E1-93A6-770B567D9A29</gtr:id><gtr:title>Ibuprofen and hydrogel-released ibuprofen in the reduction of inflammation-induced migration in melanoma cells.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/026084521d43578b23ec091cf67a5a55"><gtr:id>026084521d43578b23ec091cf67a5a55</gtr:id><gtr:otherNames>Redpath M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>aqPxbd7jboP</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401428</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93E3E424-8678-4BDD-9675-2EA16B3EFEA4</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.3  Medical devices</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>